Yes. See all information about vaccination of immunocompromised people, including revaccination considerations after HCT and for those on B-cell depleting therapies, at www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised. This is the most current statement from CDC on COVID-19 vaccination after HCT:
Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for immunocompromised people who are unvaccinated.
A patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.